Blues 2018 First-Rounder Finds New Team In Germany
German winger Dominik Bokk, 25, has signed a two-year contract with Kölner Haie, the DEL club announced on Wednesday.
Bokk, a first-round draft pick of the St. Louis Blues in 2018, is returning to the club where he played from age 14 to 17. He spent the past three seasons playing in the DEL for Löwen Frankfurt.
'I'm very excited to be playing for the Sharks starting next season and returning to Cologne after my time here with the youth team,' said Bokk. 'To be able to play for the pro team in front of Die Haie fans at Lanxess Arena fills me with pride. I want to help the team build on the strong performance of last season.'
'Dominik has developed his game further over the past few years and is one of the most well-rounded players in his age group,' said Haie sports director Matthias Baldys. We are very pleased to have him on our roster now," said Haie Sports Director Matthias Baldys. 'He took on a lot of responsibility at a young age in Frankfurt. We want to give him the opportunity to take his next steps.'
After his youth seasons in Cologne, Bokk played three and half seasons in Sweden with the Växjö Lakers, Rögle BK and Djurgarden, where he recorded 31 points in 88 SHL regular-season and playoff games.
2026 Olympics will see best German team ever The Germans have had some very good results internationally in recent years, including a silver medal at the 2018 Winter Olympics and another silver at the 2023 IIHF World Championship. They've had some very good young talent to work with but they haven't had a chance to put all of their best players together on one team since the 2010 Winter Olympics. They've improved a lot since then. In fact, it's no stretch to say the 2026 Winter Olympics will feature the greatest German ice hockey team ever assembled.
Bokk's NHL rights were traded from St. Louis to the Carolina Hurricanes in September 2019, and went to North America in early 2021 in time for the start of the pandemic-delayed AHL season. He recorded 28 points in 61 games over two seasons with the Chicago Wolves; however, despite being a 25th-overall draft pick, he was never able to crack the Carolina roster.
Bokk returned to Germany in February 2022, finishing the season with Eisbären Berlin, who won the DEL championship. Bokk has recorded 122 points in 157 DEL regular-season and playoff games with Berlin and Frankfurt.
Kölner Haie finished sixth in the DEL standings last year but made the finals, losing to Berlin. In each of the last two seasons, Kölner Haie has set a new European attendance record.
Photo © Jerome Miron-Imagn Images
Report: Kölner Haie & DEL Set New European Attendance Records; New Records In Czechia & Britain Too The Alliance of European Hockey Clubs published its annual attendance study on Wednesday,
ranking 376 clubs across 29 leagues.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
EU plan would limit Chinese device makers in Europe
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. European Union member states this week voted to support a plan to adopt measures that would restrict Chinese medical device makers' access to the EU market. The member states took the action, under the EU's International Procurement Instrument, after concluding an investigation in January that looked at China's practices in the public procurement market for medical devices. The investigation found that government practices unfairly encouraged Chinese hospitals to choose domestic manufacturers' products. 'The Commission has identified measures and practices in the Chinese procurement market that lead to discrimination against EU operators and EU-made supplies,' Olof Gill, commission spokesperson, said Thursday in an emailed statement. 'This discrimination also harms both the Chinese healthcare infrastructure, which is deprived of quality equipment, and EU businesses, with a high cost in terms of jobs and economic activity in the EU.' The commission has discussed its concerns with Chinese authorities. However, a satisfactory solution has not been proposed, and the EU had no other option than to tackle the issue through an IPI investigation, Gill wrote. The commission said it could not disclose the content of the draft IPI measure or next steps in the process. Chinese manufacturers would be prohibited from bidding on public procurement contracts worth more than 5 million euros for five years. In addition, no more than 50% of a contract's value may be subcontracted to Chinese entities or include Chinese-origin medical devices, MedTech Europe said in a statement. The trade group said it would provide further updates once the IPI measures are published in the EU's official journal. The EU investigation into China's medical device procurement practices was the first use of the IPI, which was introduced in 2022. Getting fair access to Chinese markets became more challenging for medical device companies after the country launched a program calling for domestically produced medical equipment to achieve 50% market penetration in county-level hospitals by 2020 and 70% by 2025, according to a statement from the European Chamber, which represents European businesses in China. European and Chinese leaders will meet in July at a summit in Beijing. Recommended Reading EU mulls retaliation after showing China's bias against foreign device firms Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
28 minutes ago
- Yahoo
Falcons in Germany: Delta offering limited-time flights to Berlin
The Brief Delta will offer direct flights from Atlanta to Berlin before and after the Falcons' game there this November. These are the first direct flights from Atlanta to the German capital. The flights are part of Delta's bigger plan to offer more direct flights between NFL cities. ATLANTA - For the first time ever, Delta says it will offer a direct flight from Atlanta to Berlin. What we know The limited-time flights will take place on November 5 and 6 ahead of the Atlanta Falcons' Game in Berlin on November 9. Related: Falcons to face Colts in Berlin for first-ever NFL game in Berlin Delta says it will also offer two direct flights back to Atlanta on November 10 and 11. These will be the first direct flights from Hartsfield-Jackson Atlanta International Airport to the German capital, according to Delta. All flights will have upgraded options, like Delta One and Delta Comfort, and tickets are already available. Big picture view These flights are part of Delta's plan to expand flights between major NFL cities this football season. The airline says it's adding 37 nonstop flights between different NFL cities, as well as moving 12 existing flights to larger airplanes during the NFL season. You can see all new and expanded flights on Delta's website. What they're saying "From kickoff to the final down, we're making it easier than ever to get in on the action – with new, nonstop routes and extra capacity for key games in cities like Berlin, Detroit, Kansas City, Philadelphia and more," said Delta's Vice President of North America Network Planning Amy Martin. "We know our customers love their teams, so we have timed these flights to make it faster and easier to get them to the games that matter most." The Source Information for this article came from Delta's website (embedded above).
Yahoo
33 minutes ago
- Yahoo
Pharmaris Canada to Lead Sales and Marketing for Vimy Pharma Products Across Canada
TORONTO, ON / / June 6, 2025 / Two proudly Canadian pharmaceutical companies announced today a strategic partnership that reinforces their shared commitment to serving Canadian patients. Under the agreement, Pharmaris will assume responsibility for all sales and marketing activities for Vimy Pharma product portfolio across Canada. This landmark collaboration unites two homegrown Canadian pharmaceutical organizations, both with deep roots in the Canadian healthcare landscape. The partnership exemplifies Canadian innovation and entrepreneurship in action, while strengthening domestic pharmaceutical capabilities and expertise. Built by Canadians for Canadians, both companies have demonstrated their dedication to advancing healthcare solutions that address the unique needs of the Canadian market. This alliance further cements their shared vision of making healthcare more accessible and affordable for patients from coast to coast. "Our partnership with Vimy Pharma marks a big step forward advancing access to critical medicines for Canadians,"said Michael Sine, President of Pharmaris. "This alliance demonstrates our shared commitment to putting Canadian patients first." "We are pleased to partner with Pharmaris in broadening access to essential medicines," stated Farris Smith, President of Vimy Pharma,"as we strive to improve outcomes and make a meaningful difference to patients." ABOUT PHARMARIS CANADA Pharmaris Canada is a pharmaceutical company committed to delivering high-quality healthcare products that support the well-being of Canadians. Pharmaris Canada is part of a large diversified global group based out of Vancouver, B.C started by two pharmacists. The group has business interests spanning pharmaceuticals, residential and commercial real estate, property development, hospitality, mobility solutions, and retail pharmacy operations. Pharmaris Canada offers a distinctive portfolio of over-the-counter (OTC) and generic pharmaceutical products. Our OTC range includes a Canadian-made line of iron supplements and a broad selection of German-manufactured effervescent vitamin tablets. As one of the few companies to successfully integrate branded OTC and generic medicines, Pharmaris has developed strong capabilities in brand management, prescription navigation, and market expansion. With a presence in 16 countries and a team of 585 employees, most of whom have been with the organization for over five years, Pharmaris continues to grow its global footprint through innovation and operational excellence. ABOUT VIMY PHARMA Vimy Pharma is a Canadian pharmaceutical company committed to ensuring a stable, reliable supply of essential medicines, reducing dependence on foreign sources, and supporting good-paying jobs for Canadians in life sciences and advanced manufacturing. Our products are made to the highest standards of quality and safety, meeting rigorous Health Canada guidelines. At Vimy Pharma, our team is inspired by the groundbreaking achievements of Drs. Frederick Banting and Charles Best, and James B. Collip whose discovery in Canada of insulin revolutionized treatments and changed millions of lives worldwide. Their spirit of ingenuity, collaboration, and commitment to public health continues to guide our approach as we develop and manufacture high-quality, affordable, essential medicines for Canadian health challenges. MEDIA CONTACTMichael SinePresident, Pharmaris Canadamichael@ Farris SmithFounder & President, Vimy Pharmaceuticals - 30 - SOURCE: Pharmaris View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
